Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine: Report
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
By Reuters |
Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Reuters could not immediately verify the report.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Reuters could not immediately verify the report.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersADVERTISEMENT
